MicroPort Scientific Corporation

OTCPK:MCRP.F Stock Report

Market Cap: US$1.5b

MicroPort Scientific Valuation

Is MCRP.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MCRP.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MCRP.F ($0.84) is trading below our estimate of fair value ($1.81)

Significantly Below Fair Value: MCRP.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MCRP.F?

Key metric: As MCRP.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MCRP.F. This is calculated by dividing MCRP.F's market cap by their current revenue.
What is MCRP.F's PS Ratio?
PS Ratio1.4x
SalesUS$1.03b
Market CapUS$1.46b

Price to Sales Ratio vs Peers

How does MCRP.F's PS Ratio compare to its peers?

The above table shows the PS ratio for MCRP.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.3x
INMD InMode
3.8x4.7%US$1.6b
AORT Artivion
2.9x9.7%US$1.1b
ATRC AtriCure
3.8x12.8%US$1.8b
LMAT LeMaitre Vascular
10.7x8.6%US$2.3b
MCRP.F MicroPort Scientific
1.4x15.3%US$11.3b

Price-To-Sales vs Peers: MCRP.F is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (5.3x).

Price to Sales Ratio vs Industry

How does MCRP.F's PS Ratio compare vs other companies in the US Medical Equipment Industry?

52 CompaniesPrice / SalesEstimated GrowthMarket Cap
VREX Varex Imaging
0.7x2.0%US$568.78m
ARAY Accuray
0.4x5.4%US$182.02m
NVRO Nevro
0.4x2.5%US$166.75m
KEQU Kewaunee Scientific
0.5xn/aUS$109.99m
MCRP.F 1.4xIndustry Avg. 3.3xNo. of Companies52PS02.85.68.411.214+
52 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: MCRP.F is good value based on its Price-To-Sales Ratio (1.4x) compared to the US Medical Equipment industry average (3.3x).

Price to Sales Ratio vs Fair Ratio

What is MCRP.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MCRP.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.4x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate MCRP.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MCRP.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.84
US$1.15
+36.2%
52.5%US$2.70US$0.74n/a8
Nov ’25US$0.85
US$1.14
+34.4%
52.8%US$2.70US$0.74n/a8
Oct ’25US$0.84
US$1.14
+35.7%
52.6%US$2.69US$0.74n/a8
Sep ’25n/a
US$1.50
0%
55.0%US$3.11US$0.86n/a8
Aug ’25US$0.69
US$1.50
+117.7%
54.9%US$3.10US$0.86n/a8
Jul ’25US$0.71
US$1.55
+118.1%
51.0%US$3.09US$0.86n/a8
Jun ’25n/a
US$1.62
0%
55.2%US$3.19US$0.86n/a8
May ’25n/a
US$1.70
0%
54.1%US$3.19US$0.86n/a7
Apr ’25US$0.84
US$1.78
+112.0%
49.1%US$3.19US$0.92n/a8
Mar ’25US$0.97
US$2.15
+121.0%
36.4%US$3.19US$1.07n/a8
Feb ’25n/a
US$2.28
0%
29.4%US$3.19US$1.21n/a8
Jan ’25n/a
US$2.42
0%
24.2%US$3.19US$1.21n/a8
Dec ’24US$1.58
US$2.42
+53.1%
24.2%US$3.19US$1.21n/a8
Nov ’24n/a
US$2.42
0%
24.2%US$3.19US$1.21US$0.858
Oct ’24n/a
US$2.42
0%
24.2%US$3.19US$1.21US$0.848
Sep ’24n/a
US$2.77
0%
28.4%US$3.85US$1.21n/a9
Aug ’24US$2.14
US$2.95
+37.9%
26.7%US$3.85US$1.22US$0.699
Jul ’24US$1.64
US$3.16
+92.7%
26.0%US$4.13US$1.21US$0.719
Jun ’24US$1.80
US$3.23
+79.4%
20.5%US$4.12US$1.85n/a9
May ’24n/a
US$3.23
0%
20.5%US$4.12US$1.85n/a9
Apr ’24US$2.58
US$3.22
+24.8%
19.0%US$4.12US$1.99US$0.849
Mar ’24US$2.89
US$3.23
+11.9%
19.8%US$4.12US$1.99US$0.978
Feb ’24US$3.43
US$3.01
-12.2%
18.7%US$3.82US$1.99n/a8
Jan ’24n/a
US$3.35
0%
48.8%US$7.39US$2.00n/a8
Dec ’23n/a
US$3.35
0%
48.8%US$7.39US$1.98US$1.588
Nov ’23n/a
US$3.28
0%
51.7%US$7.39US$1.47n/a8

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Centene

US$29.3b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$58.68

7D

-6.1%

1Y

-19.8%

Elevance Health

US$95.3b

Operates as a health benefits company in the United States.

ELV

US$407.04

7D

-5.2%

1Y

-12.2%

Enhabit

US$382.7m

Provides home health and hospice services in the United States.

EHAB

US$7.44

7D

-6.1%

1Y

-23.2%